Krystal Biotech Q3 Estimates Point to 29.4% Revenue Growth

John Kim

1 min read

Krystal Biotech Q3 Estimates Point to 29.4% Revenue Growth

Earnings per share are estimated at $1.92, down 27.8% year over year. Results are due before U.S. markets open Monday, Nov. 2.

By John Kim

Published Oct 30, 2026, 1:45 PM EDT

A tall clear column stands beside a shorter amber block / TokenPost.ai

Krystal Biotech (KRYS) has a third-quarter revenue estimate of $126.54 million, 29.4% above the year-earlier quarter. Earnings per share are estimated at $1.92, a 27.8% decline from a year earlier.

The company is scheduled to release results before U.S. markets open Monday, Nov. 2.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.